Key facts, as of
As of November 4, 2026, Incyte Corporation (INCY) trades at $118.97, up 15.6% over the past year. Its 52-week range runs from $89.25 to $132.60; the price is 10.3% below that high. It is 22.3% below its all-time high of $153.15, reached in March 2017. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +38.4%, against +316.3% for the S&P 500 (SPY). It sits 9.9% above its 200-day average of $108.27. Its 30-day volatility is 29.0% annualized, which we rate medium risk. It has a trailing P/E of 60.7.
Cite: Portfolio Terminal, "Incyte Corporation (INCY) stock analysis", 2026-11-04. https://portfolio-terminal.com/analyse/incy
Where it trades today
trading 69% of the way up its 52-week range
How the price has moved
How far it is from its record
Incyte Corporation (INCY) is 22.3% below its all-time high of $153.15, reached in March 2017. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +38.4%, against +316.3% for the S&P 500 (SPY).
The read, from its own figures
What its numbers say
- INCY closes below its 50-day average ($119.91) while the 50-day is still above the 200-day ($108.27): a pullback inside a longer rise, not yet a downtrend.
- At $118.97, INCY is 10.3% below its 1-year high of $132.60, set on July 28, 2026, and 33.3% above its 1-year low of $89.25 (March 24, 2026).
- Over the past month INCY rose 4.2%, from $114.13 to $118.97.
- INCY trades at 60.7x its last twelve months of earnings and 13.8x the next twelve months' estimate, so analysts expect earnings 341.0% higher.
- Its P/E is 113.5% above the 28.4x median of the 2 other biotechnology companies we track (VRTX, REGN).
- INCY's 30-day volatility, 29.0% a year, works out to a typical daily move of about 1.8%.
- Yahoo Finance puts its beta at 0.78: over five years of monthly returns, INCY moved about 0.78% for each 1% move of the S&P 500.
- The last session traded 0.2x INCY's average daily volume of the 30 sessions before it.
What would change the read
- A close back above the 50-day average, $119.91 (+0.8%), restores the uptrend; the 50-day falling 9.7% under the 200-day at $108.27 would make it a downtrend.
- A close above $132.60 (+11.5%) would be a new 1-year high; below $89.25 (−25.0%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for INCY, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Peers are the other companies Yahoo Finance files under biotechnology among the assets we track, not a full industry screen; the median counts those with a positive P/E.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for INCY by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
- Yahoo Finance quote and daily historyopen →
The candles, the averages' inputs and the quote fields used for INCY. Last refresh: Nov 4, 2026, 3:42 PM UTC.
- How Portfolio Terminal computes its figuresopen →
The methodology page behind the analytics and their refresh cadence.
- Industry classification
Yahoo Finance's industry, as stored in our list of tracked assets: Biotechnology.
What Incyte Corporation does
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784…
What analysts expect
INCY carries a buy consensus from 24 analysts, with an average price target of $130.92 versus $118.97 today (+10.0%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
INCY generated $6.01B in trailing revenue (14.0% year over year), with a 6.7% net margin, and $1.29B of free cash flow, supported by $3.82B of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $5.14B | $4.77B | $1.34B | $1.29B | $6.59 | $1.33B |
| 2024 | $4.24B | $3.93B | $101.29M | $32.62M | $0.16 | $235.17M |
| 2023 | $3.70B | $3.44B | $655.36M | $597.60M | $2.67 | $449.00M |
| 2022 | $3.39B | $3.19B | $591.63M | $340.66M | $1.53 | $892.11M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
INCY is in 16 of the 54 ETFs we track. It weighs most in XLV: 0.30% of the fund, holding #48 of 62.
Famous investors who hold it
INCY is in the latest 13F of 1 of the 15 famous investors we follow. Renaissance Technologies (Founded by Jim Simons) holds the most of it: 0.55% of the portfolio, position #26 of 2,931, as of Q2 2026.
How its figures compare with those peers
Companies in the same industry
INCY beside the other companies Yahoo Finance files under biotechnology among the assets we track (VRTX, REGN, MRNA, largest first).
INCYyou are here$118.97$24.25B
VRTXVertex Pharmaceuticals$534.86$135.57B
REGNRegeneron Pharmaceuticals$949.76$98.25B
MRNAModerna Inc.$248.36$99.15BWhat the chart is saying
Slipped under its 50-day average inside a longer uptrend.
weakening- Price is 0.8% below its 50-day average and 9.9% above its 200-day.
- RSI at 54 is neither stretched nor washed out.
- The nearest ceiling is $129.84 (+9.1%), the nearest floor $110.45 (-7.2%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
How is INCY valued right now?
Incyte Corporation trades at 60.7 times its last twelve months of earnings and 13.8 times the next twelve months' estimate (Yahoo Finance, November 4, 2026). On the chart: slipped under its 50-day average inside a longer uptrend. Price is 0.8% below its 50-day average and 9.9% above its 200-day.
What is the risk level of INCY?
Based on 30-day volatility of 29.0%, INCY has MEDIUM risk. Its beta of 0.78 means it has swung less than the S&P 500 over the last five years.
Does INCY pay dividends?
Yahoo Finance shows no dividend yield for Incyte Corporation (November 4, 2026).
How far is INCY from its all-time high?
Incyte Corporation is 22.3% below its all-time high of $153.15, reached in March 2017. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +38.4%, against +316.3% for the S&P 500 (SPY).
Which ETFs hold INCY?
16 of the 54 popular ETFs we track hold Incyte Corporation. The largest weights: XLV (0.30%), VB (0.26%), RSP (0.18%), VOOG (0.06%) and SPYG (0.05%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is INCY?
0.03%, as of September 30, 2026: INCY is holding #371 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.31 in Incyte Corporation.
Which famous investors own INCY?
Renaissance Technologies (0.55% of Founded by Jim Simons's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for INCY?
The average analyst price target for Incyte Corporation (INCY) is $130.92 based on 24 analyst estimates, about 10.0% above the current price of $118.97. The published range runs from $86.00 to $157.00.
How much revenue does INCY generate?
Incyte Corporation reported $6.01B in trailing twelve-month revenue. Revenue growth is running at 14.0% year over year. Net margin sits at 6.7%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare INCY with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.